JNJ vs. LLY, ABBV, MRK, PFE, BMY, ZTS, RPRX, CORT, JAZZ, and PRGO
Should you be buying Johnson & Johnson stock or one of its competitors? The main competitors of Johnson & Johnson include Eli Lilly and Company (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), and Perrigo (PRGO). These companies are all part of the "pharmaceuticals" industry.
Johnson & Johnson vs.
Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, community ranking, media sentiment, valuation and risk.
Johnson & Johnson has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500.
In the previous week, Eli Lilly and Company had 35 more articles in the media than Johnson & Johnson. MarketBeat recorded 107 mentions for Eli Lilly and Company and 72 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 1.29 beat Eli Lilly and Company's score of 1.11 indicating that Johnson & Johnson is being referred to more favorably in the media.
Eli Lilly and Company has a net margin of 23.51% compared to Johnson & Johnson's net margin of 18.20%. Eli Lilly and Company's return on equity of 85.24% beat Johnson & Johnson's return on equity.
Eli Lilly and Company received 101 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 70.65% of users gave Eli Lilly and Company an outperform vote while only 64.74% of users gave Johnson & Johnson an outperform vote.
Johnson & Johnson pays an annual dividend of $5.20 per share and has a dividend yield of 3.4%. Eli Lilly and Company pays an annual dividend of $6.00 per share and has a dividend yield of 0.8%. Johnson & Johnson pays out 57.8% of its earnings in the form of a dividend. Eli Lilly and Company pays out 48.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has increased its dividend for 64 consecutive years and Eli Lilly and Company has increased its dividend for 11 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Johnson & Johnson has higher revenue and earnings than Eli Lilly and Company. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.
Johnson & Johnson presently has a consensus price target of $170.88, suggesting a potential upside of 10.11%. Eli Lilly and Company has a consensus price target of $1,011.37, suggesting a potential upside of 30.74%. Given Eli Lilly and Company's stronger consensus rating and higher probable upside, analysts plainly believe Eli Lilly and Company is more favorable than Johnson & Johnson.
Summary
Eli Lilly and Company beats Johnson & Johnson on 14 of the 22 factors compared between the two stocks.
Get Johnson & Johnson News Delivered to You Automatically
Sign up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Johnson & Johnson Competitors List
Related Companies and Tools
This page (NYSE:JNJ) was last updated on 6/10/2025 by MarketBeat.com Staff
Buy JNJ Stock Free JNJ Stock Alerts